Ten women, six years: what a first-of-its-kind bone trial actually found

What happened

On 16 September 2026, the journal Cell published the results of a small trial in women with severe osteoporosis. Osteoporosis is a condition where bones become thinner and more fragile, so they break more easily. The trial was led by Jose M. Moraleda. Ten women, all over 50 and all with advanced osteoporosis, were given a single drip into a vein. The drip contained their own stem cells, taken from their own bone marrow. Before the cells were given back, the team added a tag called HCELL to them. Think of it as a postcode label. The idea is that the label helps the cells find their way to bone that needs repairing, instead of drifting around the body. The women were then followed for six years. That is a long follow-up for a first trial. The headline number in the reports was a 94% fall in fractures in the first two years, from eight fractures a year across the group to about half a fracture a year. Over the whole six years, fractures fell from 0.54 per patient per year to 0.11. The team also reported that the area of bone tissue almost doubled within four months, that pain scores fell by about 34% at two years, and that physical disability improved by about 30%.

Why this matters

Broken bones are not a small thing when you are older. A broken hip can mean months of recovery, a loss of independence, and for some people a move into care. The NHS treats osteoporosis as a serious condition for exactly that reason. Most current treatments work by slowing down the breakdown of bone, or by nudging the body to build a bit more. They help, and for many people they help a lot. But they are usually taken for years, and some people find them hard to stick with. A one-off treatment that used a person's own cells would be a very different idea. That is why this trial got attention. There is a second reason it is interesting. Doctors have often assumed that stem cells taken from older or unwell people are past their best. The researchers behind this study argue the opposite: with the right preparation, those cells did the job. If that holds up, it changes how scientists think about treating older patients with their own cells.

What the evidence actually says

Here is the part that matters most, and it is the part headlines tend to skip. Ten people is a very small number. In a group that small, one unlucky year or one lucky year can swing the percentages enormously. Going from eight fractures to half a fracture sounds dramatic. In ten people, it can also be partly chance. There was also no control group. Nobody in the trial was given a dummy treatment for comparison. That matters, because people who join trials often change other things too: they may be watched more closely, given calcium and vitamin D, encouraged to move more, or checked for falls risk. Without a comparison group, you cannot separate the cells from everything else. There is a third thing. People tend to join trials when things are bad. If you are recruited during your worst spell, the following years will often look better anyway. Statisticians call this regression to the mean, and it can make a treatment look stronger than it is. None of this makes the result worthless. A six-year follow-up is genuinely valuable, and the bone tissue measurements are an encouraging sign rather than just a feeling. The researchers themselves say larger controlled trials are needed, and that long-term durability beyond six years is unclear. So the honest summary is: promising, early, and not yet proof. This is not a treatment you can ask for. It is not licensed, and it is not available on the NHS.

Qurexa perspective

We deliver prescriptions across Lincolnshire, and bone medicines come up often. Some of them have fiddly instructions: a weekly tablet that has to be taken on an empty morning, with a full glass of water, sitting or standing upright for half an hour afterwards. It is easy to get out of step with a routine like that, and once you do, it is easy to drift. That is the practical point behind this story. A future one-off treatment would be a big deal partly because sticking with today's treatments is hard. Until then, the medicine you already have works best when you actually take it as prescribed. If your bone medicine is awkward to fit around your week, that is worth a conversation with your pharmacist rather than something to quietly give up on. There is often more flexibility than people expect.

Practical advice

If you have osteoporosis, or you have been told your bones are thinning, these are the things with solid evidence behind them today. Keep taking your prescribed treatment, and say something if it is not working for you. Side effects and awkward timings are common reasons people stop. Both can often be sorted. Ask about calcium and vitamin D. Most adults in the UK are advised to consider a vitamin D supplement in autumn and winter, and people with osteoporosis are often advised on calcium too. Do some weight-bearing and resistance exercise if you safely can. Walking, dancing, stair climbing and light strength work all put helpful load through bone. Take falls seriously. Most fractures happen because someone falls. Loose rugs, poor lighting, worn slippers and trailing cables are unglamorous but they are the real culprits. Ask your GP about a falls assessment if you have had a fall or feel unsteady. Check your other medicines. Some medicines can make you dizzy or drowsy, especially in combination. A pharmacist can review them with you. And be wary of anyone selling stem cell treatments for bone problems. Clinics abroad do advertise them. This trial does not support that, and there is no licensed stem cell treatment for osteoporosis in the UK.

What to know

A small first-in-human trial gave ten women with severe osteoporosis a single infusion of their own tagged bone marrow stem cells, and followed them for six years. Fractures fell sharply, bone tissue area nearly doubled within four months, and pain and disability scores improved. It is an encouraging early result from a respected journal. It is also ten people, with no control group, and the researchers say larger controlled trials are needed. Nothing here changes what you should do this week. What does change things this week is duller and more reliable: take the treatment you have been prescribed, keep your vitamin D and calcium in order, keep moving, and make your home harder to trip in. Sources: Cell (Elsevier), 'Autologous HCELL-engineered bone marrow stem cells in severe osteoporosis', 16 September 2026, https://doi.org/10.1016/j.cell.2026.08.017. Medical Xpress, 'Osteoporosis fractures fall by 94% in small first-in-human stem cell trial', 16 September 2026, https://medicalxpress.com/news/2026-09-osteoporosis-fractures-fall-small-human.html. NHS, 'Osteoporosis', https://www.nhs.uk/conditions/osteoporosis/. This article is for general information and does not replace advice from a doctor, pharmacist or other qualified healthcare professional.